{"name":"1ST Biotherapeutics, Inc.","slug":"1st-biotherapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Phase Ia dose-escalation part of FB849 Monotherapy","genericName":"Phase Ia dose-escalation part of FB849 Monotherapy","slug":"phase-ia-dose-escalation-part-of-fb849-monotherapy","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Phase Ia dose-escalation part of FB849 Monotherapy","genericName":"Phase Ia dose-escalation part of FB849 Monotherapy","slug":"phase-ia-dose-escalation-part-of-fb849-monotherapy","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOM2pseTNmajViNVVpT21mSFBYSFN3MlFnNGh2UFhacVVzTTh1ZS1hTWNBSWNuX0pYVTdheGthVEtzSGlhTG9UVDV3TllTN2Z2WGI0ZlgyZFNsSGtzSW8wM0VFTl9PUWtFQ09zaU5jLXlwbkJVQWNUaXVZeUZXTVF4NnhDektVTzlCakxyZzBiWE1VSFYxcGpsS2dIMm4yVks5T1pVU2ItV3VYdG16U2E5Y2JlN0dSMHJ1cksxQ2o5cmlUZ2lUV1d3SG1vMWJFdXM?oc=5","date":"2026-03-20","type":"pipeline","source":"seekingalpha.com","summary":"Boundless Bio: Underestimated Biotech With First-In-Class EcDNA Targeted Kinesin Degrader - seekingalpha.com","headline":"Boundless Bio: Underestimated Biotech With First-In-Class EcDNA Targeted Kinesin Degrader","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1IWGt0aHk5LV9Ra2l3Z2FqQXB5am1RODZZaVIydHJvM2ZMX2R6bFJ4R0VGWjAwU25CdkYzY1VocnAwcGpTcnJTNXhYVU9zanB6Sk5pbE9NVk1OMURLeHM3VEdkWGRlcnPSAWxBVV95cUxOV05WRWNUVmU1Zy1QRzNXQlBwQjlUb2xieU91ekx1SmNQcXEwQ2dxVkxtaThLd21uUzFiaE1pWEVZVVJ3dUQ1RjNTelpyb3hyLVlHa3ZyT3Y5c0ZTQUM2MFRaTFNEYkp2X2E0N3c?oc=5","date":"2026-03-05","type":"pipeline","source":"BioInformant","summary":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant","headline":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOQnhuSkZLRjFYOUZiM1hMSkpyQnZ2TTZMb0VMU1lUVEVmT3JKdjFzdGYxR0hsbEc0SWs4ZHdyOWNBSnM3VGZFLUJHc3NvcUFYRGctTTVlV2RueGN3bllSbnB5MmtUajRvQmpROUFpTXB5UDZVRWdheGNhNGQ0R2UwblV5Sy0yUWwweE5CeEVCSW40UjByRmx3dy1B?oc=5","date":"2026-01-27","type":"pipeline","source":"BioWorld News","summary":"1st Biotherapeutics closes $22M series D, preps for IPO - BioWorld News","headline":"1st Biotherapeutics closes $22M series D, preps for IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE54Q0J3MDBBQTVROVpQa1kwWDVtMzl4OVRQR1haLU8wQUdBTG4wRTJvQlcyYXVVOUdkSjdGTFBqa1llTWlBaDdrVEk3WUVfSkw0SzNBaHBxWHZFUEhSU2J4UUFHbGV2LTRyNC1GLXB30gFyQVVfeXFMTmVrN29iTGR2dW5wUERDZ0dNSU1PYlBXWGRNMEIwd3RFNm9uRXBYbHFRd0poSm8yendHRTdXMDNVSzVYZVZHcHd4TjRPenJXUUEzTzZEOUhLYUtvYXkxdE4tN29lQVpPUUtpRUVnanR5M1VR?oc=5","date":"2026-01-26","type":"pipeline","source":"koreabiomed.com","summary":"1st Biotherapeutics closes ₩31.7 bil. Series D to accelerate pipeline, IPO prep - koreabiomed.com","headline":"1st Biotherapeutics closes ₩31.7 bil. Series D to accelerate pipeline, IPO prep","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOZDZON3pNd2RvNTNrbll6Z2pHQl9sTTB6eFpZbUp2dk8xN1N3OFN5enMwbWdlcVlNMm04U3VqTG9RaEQ3eXI0eDNRblZwaEpyUFprQ01KVXZkelhVZi1hdkJReDBFVEkwdVcyb0VDeks2c2lURkVXLWRjaGpZUWt2UGNjcUs5QU9TcVRjNl94bXlHbXY2Yjh5STMyMmNQbDhZLUFtNkR4blJTa0M0S1c0S1Z2dy1ndw?oc=5","date":"2025-12-29","type":"pipeline","source":"seekingalpha.com","summary":"Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA) - seekingalpha.com","headline":"Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9iVUFUYkF6aGt3akxZT0hGaW1LLTVITDlQdFFCYUZkc2IwaDJKSHZpQ1d2VmtPWldraV9yWm9idUZab0xqcWZzdXllQ1BIaF9WUGVxcFJMNWhPakFld2QzRVg2dElTbkZjVjdzcEY3QmtFRG96SzhTT25aMkY?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxQV19SSmJGenRyTUxPR0twOHlwei1YNTVYUWNYVi1NaGoxU3NpYUdLQjNpamFnR3lKN3JXelRkeHdFWWdDeGRHUkg4YmNkcHFjLWhUNDJlVW5fX0xtQW1VUnVVdHA0d1l2X3RhTDNmUHJqUl9UUTJqZEpBVzdhLTI5SEVsS3lsODNxUG04OWdfUDE4T0hvMk9xUkVqaVNPd0dSOTMxb3U4YTZXTEttQ280SXRvek1uekJfVmZLYTFJWERNYkhoX0hyaWxHMm1Zcl9jcW1fekFyZ3I3MzNWbjlFVThCZG5aMHNDV1I3czZyZ19QZGR2cmlaNXJFSE9KVV9TejdEYXZaUEN3S1ZMNkNnR0JLSnFabXJMY3RIZmttTWx1MXVmZ0hLS0MwdE9aU2lxR2ZwajlqMG9mRzhFSEgwUw?oc=5","date":"2025-12-09","type":"pipeline","source":"PR Newswire","summary":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQVldra1VzV1gtTmxrc3hUQ2M2YTJQemI5YkhUZUFyOXkzNm9KLXR1RF9UaXQ4VG5Za3JCTkdwMV9fcDhrYWlEOHRFcnpOYmRFRkh2U2RtNTJJZmw3V3g1Y1UzVHl1bXR3S3hkT2tlNElFNjdjaTM5N1hXNHdXNDBScTVsdmczYWlfaWJLaU5tTms0Y0FCdDlwLTB3?oc=5","date":"2025-09-11","type":"trial","source":"BioPharma Dive","summary":"Child dies in Capsida study of rare disease gene therapy - BioPharma Dive","headline":"Child dies in Capsida study of rare disease gene therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPVGhudTlQdmVrczBXOEY2Z3pDTmNKSWhVNXZvM3Jka1Y3VkhKMFdZYzIyaE9fb240SklNeVhWWWppRFhERWNOZ0FSQ2d6eU9zc2JaWmdqMWdkc1Nub1pXOHk5dkpGNk1kcXJkbjJBVzZGS041dkg1ODJsYUxCOGE2bkMzMzF2RUgyTlFsZXQtOFU2VFdPenk4dzBYQ0FoVl9wWnhMT1RZSm8zZw?oc=5","date":"2025-06-10","type":"deal","source":"BioWorld News","summary":"Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock - BioWorld News","headline":"Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-01","type":"pipeline","source":"simplywall.st","summary":"Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans? - simplywall.st","headline":"Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQVlY1d3RZb1FKOXlwbzF3SWR4cERqTkJETzVYNWxTMV9fTERxMGcybjNZU2J5OUYwdE9hMW14Z3FCWUNiZ2Q1OGdTN2xFUVZfV3dic2pORG51ZUpYSlBuT3NnMnZQM3lpVmM0VXFZMHZlZ2JHQllKMWhnMGV5Q1lDT3BZV0YwcS1JclFuVUQyM0RwaWoxVXpMR2V2UVRSZw?oc=5","date":"2025-04-22","type":"pipeline","source":"Parkinson's News Today","summary":"1ST Biotherapeutics joins MJFF LRRK2 gene-targeting program - Parkinson's News Today","headline":"1ST Biotherapeutics joins MJFF LRRK2 gene-targeting program - Parkinson's News Today","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}